8-K: ZimVie Completes Sale of Spine Business to H.I.G. Capital for $375 Million, Focuses on Dental Market

ZimVie has finalized the sale of its Spine business to an affiliate of H.I.G. Capital for $375 million, marking a strategic shift to focus on its dental business.

Summary

• ZimVie has completed the sale of its Spine business to an affiliate of H.I.G. Capital for a total of $375 million.
• The consideration includes $315 million in cash and a $60 million subordinated promissory note.
• The promissory note accrues interest at 10% per annum, compounded semi-annually, and is payable in kind.
• The note matures in five and a half years or upon a change of control event.
• ZimVie expects to achieve an annualized financial profile of $455+ million in Net Sales and a 15%+ adjusted EBITDA margin one year after the deal closes.
• The company intends to use $275 million of the proceeds to pay down debt, leaving approximately $234 million in total debt and an estimated $66 million in cash as of April 2, 2024.
• ZimVie is now a pure-play dental company focused on tooth replacement and restoration solutions.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of the sale, the focus on a high-growth market, and the expected improvement in financial performance. The company is clearly positioning itself for future growth and profitability.

Positives

• The sale of the Spine business provides ZimVie with a significant cash infusion of $315 million.
• The company is now a pure-play dental business, allowing for a more focused strategy.
• ZimVie expects improved financial performance with a projected 15%+ adjusted EBITDA margin.
• The debt reduction of $275 million will improve the company's financial flexibility.
• The company has a strong portfolio of dental products and solutions.

Negatives

• The $60 million promissory note is subordinated to other debt obligations of the purchaser.
• The company's future financial performance is based on forward-looking statements and is subject to risks and uncertainties.
• The company's adjusted EBITDA margin is a non-GAAP measure and may not be directly comparable to other companies.

Risks

• ZimVie may not achieve the expected operational, strategic, and financial benefits from the sale of the Spine business.
• The company's forward-looking statements are subject to risks, uncertainties, and changes in circumstances.
• The company's ability to achieve its financial targets depends on various factors, including market conditions and execution of its strategy.
• The promissory note is subject to the financial health of the purchaser and its ability to repay the debt.

Future Outlook

ZimVie expects to achieve an annualized financial profile of $455+ million in Net Sales and a 15%+ adjusted EBITDA margin one year following the close of the deal, focusing on its pure-play dental business.

Management Comments

• Vafa Jamali, President and Chief Executive Officer, expressed excitement for the future of the company as it focuses on differentiated solutions for dental patients and providers.
• He also thanked the global Spine team members for their contributions.

Industry Context

This transaction reflects a trend of companies focusing on core business segments and divesting non-core assets. ZimVie's move to become a pure-play dental company aligns with the growing demand for dental solutions and the potential for growth in this market.

Comparison to Industry Standards

• The sale of the Spine business for $375 million is a significant transaction in the medical device industry, comparable to other divestitures of non-core assets by large medical technology companies.
• The projected 15%+ adjusted EBITDA margin is a key metric for assessing the profitability of the dental business and will be compared to industry benchmarks for dental device companies such as Straumann, Dentsply Sirona, and Envista.
• The debt reduction and focus on a pure-play dental strategy are similar to moves made by other companies seeking to improve financial performance and focus on high-growth markets.

Stakeholder Impact

• Shareholders will benefit from the company's focus on a high-growth market and improved financial performance.
• Employees in the dental business will have increased opportunities for growth and development.
• Customers will benefit from the company's focus on innovation and improved product offerings.
• Creditors will benefit from the company's debt reduction.

Next Steps

• ZimVie will focus on growing its dental business.
• The company will work to achieve its financial targets of $455+ million in net sales and a 15%+ adjusted EBITDA margin.
• ZimVie will continue to innovate and expand its product offerings in the dental market.

Key Dates

Keywords

ZimVie, Spine Business, Dental Business, H.I.G. Capital, Acquisition, Divestiture, Promissory Note, EBITDA, Debt Reduction, Net Sales, Dental Implants, Biomaterials, Digital Dentistry